Juth, N., Gustavsson, E., Henriksson, M., & Sandman, L. (2021). Should we accept a higher cost per health improvement for orphan drugs? A review and analysis of egalitarian arguments. Bioethics, 35(4), 307-314. doi:10.1111/bioe.12786
Chicago Style (17th ed.) CitationJuth, Niklas, Erik Gustavsson, Martin Henriksson, and Lars Sandman. "Should We Accept a Higher Cost Per Health Improvement for Orphan Drugs? A Review and Analysis of Egalitarian Arguments." Bioethics 35, no. 4 (2021): 307-314, https://doi.org/10.1111/bioe.12786.
MLA (9th ed.) CitationJuth, Niklas, et al. "Should We Accept a Higher Cost Per Health Improvement for Orphan Drugs? A Review and Analysis of Egalitarian Arguments." Bioethics, vol. 35, no. 4, 2021, pp. 307-314, https://doi.org/10.1111/bioe.12786.